A. M. Taburet

Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients

Radojka M. Savić, Aurélie Barrail‐Tran, Xavier Duval et al. · Clinical Pharmacology & Therapeutics · 2012 · 47 citations · Full text

Pharmacokinetic comparison of oral and local action transcutaneous flurbiprofen in healthy volunteers

A. M. Taburet, E Singlas, R. C. Glass et al. · Journal of Clinical Pharmacy and Therapeutics · 1995 · 43 citations

Pharmacokinetics of metoclopramide in patients with liver cirrhosis.

E. Magueur, Hervé Hagège, P Attali et al. · British Journal of Clinical Pharmacology · 1991 · 40 citations · Full text

Haemodialysis does not affect the pharmacokinetics of nifedipine.

H. Martre, R. Sari, A. M. Taburet et al. · British Journal of Clinical Pharmacology · 1985 · 28 citations · Full text

Lopinavir/Ritonavir Monotherapy as a Nucleoside Analogue–Sparing Strategy to Prevent HIV-1 Mother-to-Child Transmission: The ANRS 135 PRIMEVA Phase 2/3 Randomized Trial

Roland Tubiana, Laurent Mandelbrot, Jérôme Le Chenadec et al. · Clinical Infectious Diseases · 2013 · 25 citations · Full text